Human _His6BAFF/TNFSF13B (h_His6 BAFF) #5413

Recombinant human _His6BAFF (h_His6BAFF) Ala134-Leu285 (Accession #NP_006564) was expressed in human 293 cells at Cell Signaling Technology.

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant h_His6BAFF. All lots are greater than 98% pure.

Molecular Formula:

Recombinant N-terminally His6-tagged hBAFF has a calculated MW of 18,066. DTT-reduced and non-reduced protein migrate as 21 kDa polypeptides. The expected amino terminus of recombinant h_His6BAFF was verified by amino acid sequencing.

Bioactivity:

The bioactivity of recombinant h_His6BAFF was determined in a cell proliferation assay using mouse splenic B cells. The ED₅₀ of each lot is between 0.5-2 ng/ml.

Endotoxin:

Less than 0.01 ng endotoxin/1 μg h_His6BAFF.

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 10 mM DTT and 20 μg BSA per 1 μg h_His6BAFF. Cystines are not required for bioactivity. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 10 mM DTT. Cystines are not required for bioactivity.

Storage:

Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

BAFF, a member of the TNF superfamily of proteins, is a homotrimeric transmembrane protein, which is cleaved to produce a soluble cytokine (1). BAFF may also further oligomerize into 60-mer structures (1). BAFF is expressed by neutrophils, macrophages, dendritic cells, activated T cells, and epithelial cells (1,2). BAFF plays a key role in B cell development, survival, and activation (1,3,4). BAFF binds to three distinct receptors, BAFF-R, TACI, and BCMA (1). These receptors are differentially expressed during B cell development and among B cell subsets (1,2,4). While BAFF-R and BCMA bind to the homotrimeric form of BAFF, TACI only binds to membrane-bound or higher order BAFF structures (1). The BAFF/ BAFF-R interaction activates both canonical and non-canonical NF-κB pathways, PI3K/Akt, and mTor signaling (2,4). Activation of the noncanonical NF-κB pathway via BAFF-R is negatively regulated by TRAF3 (5). Elevated levels of BAFF may exacerbate many autoimmune disorders, making it an attractive therapeutic target (2).

1. Mackay, F. and Schneider, P. (2009) Nat Rev Immunol 9, 491-502.
2. Moisini, I. and Davidson, A. (2009) Clin Exp Immunol 158, 155-63.
3. Schiemann, B. et al. (2001) Science 293, 2111-4.
4. Khan, W.N. (2009) J Immunol 183, 3561-7.
5. Gardam, S. et al. (2008) Immunity 28, 391-401.

• Data sheet (739KB)
• MSDS PDF